Author(s):
Priyanka M. Sagar, S.D. Mankar, S. B. Dighe
Email(s):
priyankasagar3322@gmail.com
DOI:
10.52711/2231-5675.2023.00036 
Address:
Priyanka M. Sagar*, S.D. Mankar, S. B. Dighe
Department of Quality Assurance Techniques, Pravara Rural College of Pharmacy, Pravaranagar, Tal: Rahta, Dist: Ahmednagar 413737, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 3,
Year - 2023
ABSTRACT:
Diabetes mellitus (DM) is a metabolic condition characterized by hyperglycemia, glycosuria, hyperglycemia, a negative nitrogen balance, and occasionally ketonemia. The type 2 sodium-dependent glucose co-transporters (SGLT), which are in charge of roughly 90% of the reabsorption of glucose from the glomerulus, are subject to strong and selective inhibition by ertugliflozin. This review's primary objective is to highlight the development and validation of analytical methods employing chromatographic and spectrophotometric techniques for ertugliflozin and combination products in bulk and pharmaceutical dose forms. RP-HPLC, UV, UPLC, and LC-MS techniques are used to determine the dosage of ertugliflozin when it is combined with metformin and sitagliptin. Spectrometric techniques for ertugliflozin in combination with metformin or sitagliptin contain parameters like solvent, wavelength, linearity, LOD, LOQ, etc., and HPLC methods for ertugliflozin in combination with metformin or sitagliptin include parameters like stationary phase, mobile phase, RT, detection wavelength, LOD, LOQ, etc. Discussions on the separation requirements for ertugliflozin in combination with metformin or sitagliptin are also addressed throughout this review.
Cite this article:
Priyanka M. Sagar, S.D. Mankar, S. B. Dighe. An Overview on Analytical Method Development and Validation for Ertugliflozin in Bulk and Pharmaceutical Dosage form. Asian Journal of Pharmaceutical Analysis. 2023; 13(3):222-8. doi: 10.52711/2231-5675.2023.00036
Cite(Electronic):
Priyanka M. Sagar, S.D. Mankar, S. B. Dighe. An Overview on Analytical Method Development and Validation for Ertugliflozin in Bulk and Pharmaceutical Dosage form. Asian Journal of Pharmaceutical Analysis. 2023; 13(3):222-8. doi: 10.52711/2231-5675.2023.00036 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2023-13-3-12
REFERENCES:
1. Cinti F, Moffa S, Impronta F, Cefalo Cma, Sun Va, Sorice G, Et Al. Spotlight on Ertugliflozin and Its Potential in The Treatment of Type 2 Diabetes: Evidence to Date. Vol. 11, Drug Design, Development and Therapy. Dove Medical Press Ltd.; 2017. P. 2905–19.
2. Rajeev Goyal, Ishwarlal Jialal, Diabetes Mellitus Type 2, Stat Pearls Publishing, Treasure Island (FL), 2022, PMID: 30020625
3. International Diabetes Federation (2021): Statistics of Diabetes Mellitus. Retrieved From Idf.Org/Aboutdiabetes/What-Is-Diabetes/Facts-Figures.Html.
4. Rang Hp, Dale Mm, Ritter Jm, Flower Rj and Henderson G (2012): Rang and Dale's Pharmacology. Edinburgh, Churchill Livingstone, 7th Edn, Pp 377-383.
5. Vivianne K. Nguyen And John R. White, Jr, “Overview of Ertugliflozin, PubMed Central. 2019; 37(2): 176–178.
6. https://www.drugs.com
7. Https://Medlineplus.Gov
8. Https://Www.Rxlist.Com
9. Https://Www.Ncbi.Nlm.Nih.Gov
10. Https://Pubchem.Ncbi.Nlm.Nih.Gov
11. Https://Www.Scbt.Com/P/Sitagliptin-486460-32-6
12. Https://Www.Trc-Canada.Com/Product-Detail/?E635090
13. Https://Www.Medindia.Net/Doctors/Drug_Information
14. Https://Go.Drugbank.Com/Drugs/Db11827
15. Https://Go.Drugbank.Com/Drugs/Db01261
16. Https://Www.Sciencedirect.Com/Topics/Pharmacology-Toxicology-And-Pharmaceutical-Science/Sitagliptin
17. Https://Go.Drugbank.Com/Drugs/Db00331
18. Nikolas Kovacich, Ertugliflozin (Steglatro): A New Option for Sglt2 Inhibition, Pmc, 2018 Dec; 43(12): 736–742.
19. Https://Tmedweb.Tulane.Edu/Pharmwiki/Doku.Php/Sitagliptin
20. Https://Www.Merckconnect.Com/Januvia/Mechanism-of Action/Sitagliptin
21. Leclerc I, Woltersdorf WW, Da Silva Xavier G, Rowe Rl, Cross SE, Korbutt GS. Metformin but Not Leptin, Regulates Amp-Activated Protein Kinase in Pancreatic Islets: Impact on Glucose-Stimulated Insulin Secretion. Am J Physiol Endocrino Metab. 2004: 286(6): E1023-31. Epub 2004 Feb 10.
22. Https://Chem.Libretexts.Org/Bookshelves/Physical_And_Theoretical_Chemistry_Textbook_Maps/Supplemental_Modules.
23. M. Anjali. Method Development and Validation of Ertugliflozin and Sitagliptin by Using Simultaneous Equation Method Journal of Innovation in Pharmaceutical Sciences. 2019;3(1): 22-28.
24. Https://Www.Azom.Com/Article chromatography.
25. Aleti Rajareddy And A. Divya. Stability Indicating Rp-Hplc Method Development and Validation for The Simultaneous Estimation of Ertugliflozin and Sitagliptin in Bulk and Pharmaceutical Dosage Form. World J Pharm Sci. 2021; 9(11): 68-75.
26. B. Rajeswari A, N. Saritha B, And N. Devanna. Validated Rp-HPLC Method Development for Estimation of Ertugliflozin and Sitagliptin in Bulk and Dosage Forms. JPRI. 2022,34(20b): 22-26.
27. C. Parthiban, Aneesa, M. Sudhakar. Analytical Method Development and Validation for Simultaneous Estimation of Sitagliptin and Ertugliflozin in Bulk and Pharmaceutical Dosage Form by RP-HPLC. World J Pharm Sci. 2021; 9(12): 206-211.
28. Ch. Rani And M. Pravalika. Analytical Method Development and Validation for Simultaneous Estimation of Ertugliflozin and Sitagliptin in Pharmaceutical Dosage Form by RP-HPLC. European Journal of Biomedical and Pharmaceutical Sciences. 2021, 8 (10) 261-267.
29. D. China Babu, C. Madhusudhana Chetty and SK. Mastanamma. Novel Stress Indicating RP-HPLC Method Development and Validation for The Simultaneous Estimation of Ertugliflozin and Sitagliptin in Bulk and Its Formulation. Orient. J. Chem. 2018, 34(5), 2554-2561.
30. G. Ananya, M. Ajitha. Stability Indicating Rp-Hplc Method Development and Validation for Simultaneous Estimation of Ertugliflozin and Sitagliptin in Bulk and Pharmaceutical Dosage Form. World J Pharm Sci. 2022; 10(01): 52-58
31. M. Laxm, R. V. Valli Kumari, S. Marakatham and M. Sathish Kumar. RP-HPLC Method Development and Validation for Simultaneous Estimation of Ertugliflozin and Sitagliptin in Bulk and Tablet Dosage Forms. Indian Journal of Applied Research. 9(10): 9-13.
32. P. Venkateswara Rao, A Lakshmana Rao S Prasad. Simultaneous Estimation of Ertugliflozin and Sitagliptin in Bulk and Pharmaceutical Dosage Form Its Validation Parametrs as Per ICH Guidelines. Indo American Journal of Pharmaceutical Sciences. 2018; 5(04): 2616–27.
33. Raju M, Hanzal Fathima, Hafsa Siddiqua and Sunil Kumar Chaitanya. P. Development and Validation of An Analytical Method for The Simultaneous Estimation of Ertugliflozin and Sitagliptin in Bulk and Pharmaceutical Dosage Form. J. Global Trends Pharm Sci. 2021, 12 (2), 9378 – 9386
34. Vamseekrishna G, Nimmakoori Divya, Padmata Navya and Tumu Sravani. A Novel Stress Indicating RP-HPLC Method for Estimation of Ertugliflozin and Sitagliptin in Combined Dosage Form. 2022; 25(2): 94-109.
35. Kadali Jagadeesh, Annapurna N. Stability Indicating Method Development and Validation of Metformin and Ertugliflozin by High-Performance Liquid Chromatography with Pda Detection and its Application to Tablet Dosage Form. Asian J Pharm Clin Res. 2019; 12(3): 353-358.
36. Syed Wajahat Shafaat, Aejaz Ahmed, G. J. Khan, Shaikh Anas and Absar A. Qureshi. Analytical Method Development and Validation for Simultaneous Estimation of Ertugliflozin and Metformin Hcl in Bulk and Pharmaceutical Dosage Form by HPLC. International Journal of Pharmaceutical Sciences and Research. 11(1): 226-232.
37. A Lakshmana Rao. Stability Indicating RP-HPLC Method For Simultaneous Estimation of Metformin and Ertugliflozin. Journal of Pharmaceutical and Medicinal Chemistry. 2019; 5(2): 65-73.
38. Bhawani Sunkara. Stability indicating method development and validation for simultaneous estimation and quantification of Ertugliflozin and Metformin in bulk and tablet dosage form. Future. Journal of Pharmaceutical Sciences. 2021; 7(32): 1-10.
39. Jyosthna Sri Lakshmi Durga Savala, SK Abdul Rahaman. RP-HPLC Method Development and Validation for Simultaneous Determination of Ertugliflozin and Metformin in Pharmaceutical Dosage Forms. 2021; 12(4): 1226-1264.
40. Suleman S. Khoja, Laxman J. Patel. Development and Validation of New Analytical RP-HPLC Method for the Estimation of Antidiabetic Drugs Metformin Hydrochloride and Ertugliflozin in Combined Pharmaceutical Dosage Form. 2021: 11(1): 62-69.
41. Tahir Nizami, Birendra Shrivastava and Pankaj Sharma. Analytical method development and validation for simultaneous estimation of Ertugliflozin and Metformin in tablet dosage form by RP-HPLC method. 2018; 9(7): 5854-5859.
42. Rao P V, Rao A L, Svum P. Development and Validation of New Stability Indicating Reversed-Phase High-Performance Liquid Chromatography Method for Simultaneous Determination of Metformin Hydrochloride and Ertugliflozin in Bulk and Pharmaceutical Dosage Form. Asian J Pharm Clin Res. 2019; 12(1): 235-240
43. Kumari, KS, and Bandhakavi. Development and validation of stability-indicating RP-HPLC method for the simultaneous determination of ertugliflozin pidolate and metformin hydrochloride in bulk and tablets. Future Journal of Pharmaceutical Sciences. 2020; 6 (1): 1-10.
44. Jumde HS, Mankar SD. Review on development of Analytical Method and Validation by Reverse Phase–High Performance Liquid Chromatography. Asian Journal of Pharmacy and Technology. 2022;12(2):179-82.
45. Suleman S. Khoja and Laxman J. Pate. Development and Validation of New Analytical LCMS/MS Method for the Estimation of Antidiabetic Drugs Ertugliflozin and Sitagliptin in Combined Pharmaceutical Dosage form. 2021; 33(30A): 194-204.
46. P Venkateswarao Rao, A Lakshmana Rao, SVUM Prasad. Rapid quantitative estimation of metformin and ertugliflozin in rat plasma by liquid chromatography-tandem mass spectroscopy and its application to pharmacokinetic studies. 2021; 20: 1–7.
47. P. Geetha Bhavani, D. Akila Devi. Development and Validation of Stability Indicating UPLC Method for the Simultaneous Estimation of Drugs in Combined Dosage Forms using Quality by Design Approach. Asian J. Pharm. Ana. 2020; 10(3):158-164.
48. Ramya kuber and Swetha Addanki. Novel stability-indicating RP-UPLC method for simultaneous estimation of sitagliptin and ertugliflozin in bulk and pharmaceutical formulations, B and Addanki Future Journal of Pharmaceutical Sciences. 2021; 7(86): 1-10
49. V. Mohan Goud, D Sai Prasanna, Shymala, P. Sirisha, JVC Sharma. Stability Indicating UPLC Method Development and Validation for Simultaneous Determination of Ertugliflozin and Sitagliptin, Am. J. PharmTech Res. 2019; 9(01): 2249-3387.